Medicare AdvantageCoverageMedium impact
MA08.151e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Independence Blue Cross·Neurology, Internal Medicine, Geriatrics +1 more·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated its policy for monoclonal antibodies directed against amyloid for Alzheimer's disease treatment, affecting coverage criteria, reimbursement positions, medical necessity requirements, and coding guidelines. This represents a comprehensive policy overhaul for this specialized neurological treatment.
Action Required
Before January 1, 2026: Billing team must review and update procedures for monoclonal antibody treatments for Alzheimer's disease in Medicare Advantage patients. Update prior authorization workflows, medical necessity documentation requirements, and coding guidelines per the new policy. Providers treating Alzheimer's patients should review updated coverage criteria to ensure compliance.